Literature DB >> 34339541

A novel melatonin-regulated lncRNA suppresses TPA-induced oral cancer cell motility through replenishing PRUNE2 expression.

Shih-Chi Su1,2,3, Chia-Ming Yeh4,5, Chiao-Wen Lin6,7, Yi-Hsien Hsieh4,5, Chun-Yi Chuang8,9, Chih-Hsin Tang10,11, Yi-Chan Lee12,13, Shun-Fa Yang4,5.   

Abstract

The inhibitory effect of melatonin on cancer cell dissemination is well established, yet the functional involvement of lncRNAs in melatonin signaling remains poorly understood. In this study, we identified a melatonin-attenuated lncRNA acting as a potential melatonin-regulated oral cancer stimulator (MROS-1). Downregulation of MROS-1 by melatonin suppressed TPA-induced oral cancer migration through replenishing the protein expression of prune homolog 2 (PRUNE2), which functioned as a tumor suppressor in oral cancer. Melatonin-mediated MROS-1/PRUNE2 expression and cell motility in oral cancer were regulated largely through the activation of JAK-STAT pathway. In addition, MROS-1, preferentially localized in the nuclei, promoted oral cancer migration in an epigenetic mechanism in which it modulates PRUNE2 expression by interacting with a member of the DNA methylation machinery, DNA methyltransferase 3A (DNMT3A). Higher methylation levels of PRUNE2 promoter were associated with nodal metastases and inversely correlated with PRUNE2 expression in head and neck cancer. Collectively, these findings suggest that MROS-1, serving as a functional mediator of melatonin signaling, could predispose patients with oral cancer to metastasize and may be implicated as a potential target for antimetastatic therapies.
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  lncRNA; melatonin; metastasis; oral cancer

Mesh:

Substances:

Year:  2021        PMID: 34339541     DOI: 10.1111/jpi.12760

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  20 in total

1.  Identification of lncRNAs based on different patterns of immune infiltration in gastric cancer.

Authors:  Shujia Chen; Xinyu Ben; Lianyi Guo; Xiaofei Li
Journal:  J Gastrointest Oncol       Date:  2022-02

2.  The impact of ALDH7A1 variants in oral cancer development and prognosis.

Authors:  Hsueh-Ju Lu; Chun-Yi Chuang; Mu-Kuan Chen; Chun-Wen Su; Wei-En Yang; Chia-Ming Yeh; Kuan-Ming Lai; Chih-Hsin Tang; Chiao-Wen Lin; Shun-Fa Yang
Journal:  Aging (Albany NY)       Date:  2022-05-25       Impact factor: 5.955

3.  Impact of Long Noncoding RNA LINC00673 Genetic Variants on Susceptibility to Diabetic Retinopathy.

Authors:  Chih-Chun Chuang; Yi-Sun Yang; Edy Kornelius; Chien-Ning Huang; Min-Yen Hsu; Chia-Yi Lee; Shun-Fa Yang
Journal:  Front Genet       Date:  2022-04-25       Impact factor: 4.772

4.  LncRNA-COX2 inhibits Fibroblast Activation and Epidural Fibrosis by Targeting EGR1.

Authors:  Lei Yang; Shengnai Zheng; Dawei Ge; Mingjie Xia; Haijun Li; Jian Tang
Journal:  Int J Biol Sci       Date:  2022-01-16       Impact factor: 6.580

5.  Arctiin Inhibits Cervical Cancer Cell Migration and Invasion through Suppression of S100A4 Expression via PI3K/Akt Pathway.

Authors:  Chung-Yuan Lee; Min-Chieh Hsin; Pei-Ni Chen; Chiao-Wen Lin; Po-Hui Wang; Shun-Fa Yang; Yi-Hsuan Hsiao
Journal:  Pharmaceutics       Date:  2022-02-05       Impact factor: 6.321

Review 6.  Use of Melatonin in Cancer Treatment: Where Are We?

Authors:  Leilei Wang; Chuan Wang; Wing Shan Choi
Journal:  Int J Mol Sci       Date:  2022-03-29       Impact factor: 5.923

Review 7.  LncRNA-mediated DNA methylation: an emerging mechanism in cancer and beyond.

Authors:  Wanxu Huang; Hua Li; Qingsong Yu; Wei Xiao; Dan Ohtan Wang
Journal:  J Exp Clin Cancer Res       Date:  2022-03-15

8.  Curcumin analog HO-3867 triggers apoptotic pathways through activating JNK1/2 signalling in human oral squamous cell carcinoma cells.

Authors:  Chi-Wei Chen; Ming-Ju Hsieh; Po-Chung Ju; Yi-Hsien Hsieh; Chun-Wen Su; Yen-Lin Chen; Shun-Fa Yang; Chiao-Wen Lin
Journal:  J Cell Mol Med       Date:  2022-02-21       Impact factor: 5.310

9.  PRUNE2 inhibits progression of colorectal cancer in vitro and in vivo.

Authors:  Ting Li; Silin Huang; Wei Yan; Yu Zhang; Qiang Guo
Journal:  Exp Ther Med       Date:  2021-12-27       Impact factor: 2.447

Review 10.  Usefulness of Melatonin and Other Compounds as Antioxidants and Epidrugs in the Treatment of Head and Neck Cancer.

Authors:  Joaquín Guerra; Jesús Devesa
Journal:  Antioxidants (Basel)       Date:  2021-12-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.